BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30446580)

  • 21. Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making.
    Chahal M; Pleasance E; Grewal J; Zhao E; Ng T; Chapman E; Jones MR; Shen Y; Mungall KL; Bonakdar M; Taylor GA; Ma Y; Mungall AJ; Moore RA; Lim H; Renouf D; Yip S; Jones SJM; Marra MA; Laskin J
    Cold Spring Harb Mol Case Stud; 2018 Apr; 4(2):. PubMed ID: 29610392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness.
    Serie DJ; Joseph RW; Cheville JC; Ho TH; Parasramka M; Hilton T; Thompson RH; Leibovich BC; Parker AS; Eckel-Passow JE
    Eur Urol; 2017 Jun; 71(6):979-985. PubMed ID: 27899233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models.
    Broutin S; Ameur N; Lacroix L; Robert T; Petit B; Oumata N; Talbot M; Caillou B; Schlumberger M; Dupuy C; Bidart JM
    Clin Cancer Res; 2011 Apr; 17(7):2044-54. PubMed ID: 21325074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
    Saunus JM; Quinn MC; Patch AM; Pearson JV; Bailey PJ; Nones K; McCart Reed AE; Miller D; Wilson PJ; Al-Ejeh F; Mariasegaram M; Lau Q; Withers T; Jeffree RL; Reid LE; Da Silva L; Matsika A; Niland CM; Cummings MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Anderson MJ; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Taylor D; Waddell N; Wood S; Xu Q; Kassahn KS; Narayanan V; Taib NA; Teo SH; Chow YP; kConFab ; Jat PS; Brandner S; Flanagan AM; Khanna KK; Chenevix-Trench G; Grimmond SM; Simpson PT; Waddell N; Lakhani SR
    J Pathol; 2015 Nov; 237(3):363-78. PubMed ID: 26172396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer.
    Alshalalfa M; Schliekelman M; Shin H; Erho N; Davicioni E
    Biol Cell; 2015 Jul; 107(7):232-44. PubMed ID: 25900404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular and Genomic Profiling to Identify Actionable Targets in Chromophobe Renal Cell Cancer.
    Abbosh P; Sundararajan S; Millis SZ; Hauben A; Reddy S; Geynisman DM; Uzzo R
    Eur Urol Focus; 2018 Dec; 4(6):969-971. PubMed ID: 28753842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRα genotype evaluated by next generation sequencing (NGS).
    Saponara M; Urbini M; Astolfi A; Indio V; Ercolani G; Del Gaudio M; Santini D; Pirini MG; Fiorentino M; Nannini M; Lolli C; Mandrioli A; Gatto L; Brandi G; Biasco G; Pinna AD; Pantaleo MA
    Oncotarget; 2015 Dec; 6(39):42243-57. PubMed ID: 26544626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A five-gene signature may predict sunitinib sensitivity and serve as prognostic biomarkers for renal cell carcinoma.
    Chen YL; Ge GJ; Qi C; Wang H; Wang HL; Li LY; Li GH; Xia LQ
    J Cell Physiol; 2018 Oct; 233(10):6649-6660. PubMed ID: 29327492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection and genomic characterization of a mammary-like adenocarcinoma.
    Grewal JK; Eirew P; Jones M; Chiu K; Tessier-Cloutier B; Karnezis AN; Karsan A; Mungall A; Zhou C; Yip S; Tinker AV; Laskin J; Marra M; Jones SJM
    Cold Spring Harb Mol Case Stud; 2017 Nov; 3(6):. PubMed ID: 28877932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA‑mRNA integrated analysis based on a case of well‑differentiated thyroid cancer with both metastasis and metastatic recurrence.
    Zhang YJ; Ma YS; Xia Q; Yu F; Lv ZW; Jia CY; Jiang XX; Zhang L; Shao YC; Xie WT; Lu GX; Yv XQ; Zhong P; Fu D; Wang XF
    Oncol Rep; 2018 Dec; 40(6):3803-3811. PubMed ID: 30272320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma.
    Nagao K; Shinohara N; Smit F; de Weijert M; Jannink S; Owada Y; Mulders P; Oosterwijk E; Matsuyama H
    BMC Cancer; 2018 Nov; 18(1):1114. PubMed ID: 30442117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model.
    Xu L; Tong R; Cochran DM; Jain RK
    Cancer Res; 2005 Jul; 65(13):5711-9. PubMed ID: 15994946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binning somatic mutations based on biological knowledge for predicting survival: an application in renal cell carcinoma.
    Kim D; Li R; Dudek SM; Wallace JR; Ritchie MD
    Pac Symp Biocomput; 2015; ():96-107. PubMed ID: 25592572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
    Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
    Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential.
    Zhang T; Sun HC; Xu Y; Zhang KZ; Wang L; Qin LX; Wu WZ; Liu YK; Ye SL; Tang ZY
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8557-63. PubMed ID: 16361537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
    Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
    BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.
    Maruschke M; Reuter D; Koczan D; Hakenberg OW; Thiesen HJ
    BJU Int; 2011 Jul; 108(2 Pt 2):E29-35. PubMed ID: 21435154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.
    Glinsky GV
    Cancer Lett; 2016 Oct; 381(1):176-93. PubMed ID: 27497790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma.
    Scott MC; Temiz NA; Sarver AE; LaRue RS; Rathe SK; Varshney J; Wolf NK; Moriarity BS; O'Brien TD; Spector LG; Largaespada DA; Modiano JF; Subramanian S; Sarver AL
    Cancer Res; 2018 Jan; 78(2):326-337. PubMed ID: 29066513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.